Disparities and therapeutic advances in cystic fibrosis

John B. Palla*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Cystic fibrosis (CF) has seen a multitude of therapeutic advances targeting its downstream effects. This has led to a steady increase in survival over the past few decades. The recent development of disease-modifying drugs targeting the underlying CFTR mutation has revolutionized treatment for CF. Despite these advances, individuals with CF who are racial and ethnic minorities, from low socioeconomic status, or female sex have worse clinical outcomes. The inequitable access to CFTR modulators from cost and/or genetic eligibility has the potential to further worsen the existing health disparities seen within the CF community.

Original languageEnglish (US)
JournalPediatric Pulmonology
StateAccepted/In press - 2023


  • CFTR modulator
  • cystic fibrosis
  • ethnicity
  • health disparity
  • race
  • sex

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Disparities and therapeutic advances in cystic fibrosis'. Together they form a unique fingerprint.

Cite this